Iron chelation in thalassemia: Combined or monotherapy? The Egyptian experience

Annals of Hematology

Volumn 87, Issue 7, 2008, Pages 545-550

  El Beshlawy, Amal ^a   Manz, Chantal ^b   Naja, Mohammed ^c   Eltagui, Mona ^a   Tarabishi, Claudia ^a   Youssry, Ilham ^a   Sobh, Hewida ^a   Hamdy, Mona ^a   Sharaf, Iman ^a   Mostafa, Azza ^a   Shaker, Olfat ^a   Hoffbrand, A V ^d   Taher, Ali ^c,e  

^a CAIRO UNIVERSITY   (Egypt)

^b Lipomed AG   (Switzerland)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e Chronic Care Center Hazmieh   (Lebanon)

Author keywords

Combination therapy; Efficacy; Egypt; Monotherapy; Thalassemia major

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; ALLERGY; ANOREXIA; ARTHROPATHY; ARTICLE; BACKACHE; BLOOD TRANSFUSION; BONE PAIN; CHILD; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; FERRITIN BLOOD LEVEL; FEVER; HEART FUNCTION; HUMAN; INSOMNIA; IRON OVERLOAD; JAUNDICE; KNEE DISEASE; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN ALLERGY; SKIN SWELLING; SKIN TOXICITY; THALASSEMIA MAJOR; VOMITING; WEAKNESS;

ADOLESCENT; ADULT; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EGYPT; FEMALE; FERRITINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MALE; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; PYRIDONES; THALASSEMIA;

EID: 44449104925     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0471-2     Document Type: Article

References (17)

1. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ (2002) Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron levels and ventricular function in beta thalassemia. Lancet 360:516-520
2. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, Galimberti M, Polchi P, Lucarelli G (2000) Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 343:327-331
3. Balveer K, Pyar K, Wonke B (2002) Combined oral and parental iron chelation in beta thalassemia major. Med J Malaysia 55:493-497
4. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A (2006) Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 107:3733-3737
5. Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Trica F (2000) Safety profile of the oral iron chelator deferiprone: A multicenter study. Br J Haematol 108:305-312
6. Daar S, Pathare AV (2006) Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol 85:315-319
7. Giardina PJ, Grady RW (2001) Chelation therapy in b-thalassemia: An optimistic update. Sem Hematol 38:360-366
8. Grady RW, Berdoukas V, Rachmilewitz E, Galanello R, Borgna-Pignatti C, Giardina PJ (2000) Iron chelation therapy: Optimizing chelation therapy: combining deferiprone and desferrioxamine [abstract]. Blood 96(Suppl 1):604a
9. Hoffbrand AV (2005) Deferiprone therapy for transfusional iron overload. Best practice and research. Clinical Haematology 18:299-317
10. Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, Drakaki K, Kaloumenou I, Galani A, Kattamis C (2006) Iron chelation treatment with combined therapy with deferiprone and deferioxamine: A 12-month trial. Blood Cells Mol Dis 36:21-25
11. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C (2001) Exploring the "iron shuttle" hypothesis in chelation therapy: Effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 138:130-138
12. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A (2003) Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassemia patients. Br J Haematol 121:187-189
13. Origa R, Bina P, Agus A, Crobn G, Defraia E, Dessi C, Leoni G, Muroni Pier P, Galanello R (2005) Combined therapy with deferiprone and desferrioxamine in thalassemia major. Hematologica 90:1309-1314
14. Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH (2003) Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol 70:392-397
15. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R (2006) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107:3738-3744
16. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ (2007) A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115:1876-1884
17. Wonke B, Wright C, Hoffbrand AV (1998) Combined therapy with deferiprone and desferrioxamine. Br J Haematol 103:361-364